Apatinib in recurrent or metastatic head and neck cancer patients.

e18010 Background: Apatinib is a small tyrosine kinase inhibitor targeting the vascular endogenous growth receptor 2 (VEGFR-2) that shows potent antitumor activities in various advanced cancers via inhibition of neo-angiogenesis. The effect apatinib recurrent or metastatic head and neck has not been fully demonstrated. Methods: Patients with consecutively treated our institute by from January 2015 to December 2020 were enrolled. Daily 250 mg 500 was given without chemotherapy according patients' tolerance. A part patients also received palliative radiotherapy. Disease response, treatment-related toxicities patient survival analyzed. Toxicity assessed CTCAE v4.0. Kaplan-Meier analysis used estimate overall survival. R software (version 3.6.3) for statistical analysis. Results: total 73 enrolled this study. There 59 males 14 females median age 55 (range: 27-80) years. Most had performance status 0 (15/73, 20.5%) 1 (51/73, 69.9%). 29 oral cavity cancers, 20 nasopharyngeal carcinomas, 8 salivary gland 7 nasal paranasal sinus 9 other malignancies. Pathologically, 47 squamous cell carcinoma, 18 adenoid cystic rest adenocarcinoma, sarcoma melanoma. majority diseases (57/74, 78.1%). Nine (12.3%) as first-line treatment, 22 (30.1%) second-line 42 (57.5%) more than treatments. Forty S-1 capecitabine chemotherapy, nab-paclitaxel gemcitabine. Ten most frequent anemia (37/73, 50.7%), leucopenia (27/73, 37.0%), thrombocytopenia (20/73, 27.4%), proteinuria arterial hypertension (17/73, 23.3%), hand-foot syndrome 23.3%). Hemorrhage occurred 10 (13.7%) patients. No treatment-associated death noted. follow-up 29.9 months. Fifty-six evaluable tumor response. Complete response Partial seen 3 stable disease (29/56, 51.8%) progressive (23/56, 41.1%). By end last follow-up, 33 died progression. 29.6 Conclusions: showed modest cancers. side effects manageable. warrants further studies larger-scale randomized studies.